BioSpace News Archive

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced it has closed an oversubscribed $30 mil

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) se

More than 8.5 million people in the U.S. today are living with chronic wounds at a cost to the U.S. healthcare system of $30 billion annually. Tissue Analytics, a Net Health company, recently presented a webinar to provide

Genome Medical , a leading telegenomics technology and services company democratizing access to genomic-based medicine, today announced that it has raised $14 million to expand its clinical genetics care and oper

Battelle has directed philanthropic giving to the Columbus Urban League, Equal Justice Initiative and United Negro College Fund in the form of $100,000 gifts to each.

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, announced the appointment of Adrian W. Burke as Senior Vice President of Operations.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com) today announced the official launch of its new RenovaCare R&D Innovation Center in Berlin, Germany, where the Company’s patented technologies for isolating and spraying self-donated stem cells to regenerate tissues and organs have been under development alongside new product initiatives

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced that Ton Schumacher, Ph.D., Principal Investigator at the Netherlands Cancer Institute and chair of Allogene’s Scientific Advisory Board, has been award

Designation would provide 10-year period of marketing exclusivity in the European Union after product approval Patients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk myelodysplastic syndromes MENLO PARK, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinio

RhoVac AB (“RhoVac”) is published in the June edition of MedNous, through a written commentary by CEO Anders Månsson.